Arcutis posts Q2 2026 profit as ZORYVE sales climb, raises full-year guidance
The company reported $129.9 million in ZORYVE sales for the quarter and lifted 2026 revenue guidance to $525 million-$540 million.
SEC filing
Latest
4 stories
Wednesday, September 9
Friday, August 7
Arcutis posts pediatric PK results for topical roflumilast in plaque psoriasis
Wednesday, August 5
Thursday, July 16
Arcutis adds Mirum CEO Chris Peetz to board of directors
Arcutis Biotherapeutics expanded its board to ten members, naming Mirum Pharmaceuticals co-founder and CEO Christopher Peetz as a new independent Class III director effective July 15, 2026.
SEC filing